Skip to main content
Top
Published in: Gut Pathogens 1/2020

Open Access 01-12-2020 | Expectoration | Research

Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis: an exploratory study

Authors: Marcus M. Mücke, Sabrina Rüschenbaum, Amelie Mayer, Victoria T. Mücke, Katharina M. Schwarzkopf, Stefan Zeuzem, Jan Kehrmann, René Scholtysik, Christian M. Lange

Published in: Gut Pathogens | Issue 1/2020

Login to get access

Abstract

Introduction

Quinolone prophylaxis is recommended for patients with advanced cirrhosis at high risk of spontaneous bacterial peritonitis (SBP) or with prior SBP. Yet, the impact of long-term antibiotic prophylaxis on the microbiome of these patients is poorly characterized.

Methods

Patients with liver cirrhosis receiving long-term quinolone prophylaxis to prevent SBP were prospectively included and sputum and stool samples were obtained at baseline, 1, 4 and 12 weeks thereafter. Both bacterial DNA and RNA were assessed with 16S rRNA sequencing. Relative abundance, alpha and beta diversity were calculated and correlated with clinical outcome.

Results

Overall, 35 stool and 19 sputum samples were obtained from 11 patients. Two patients died (day 9 and 12) all others were followed for 180 days. Reduction of Shannon diversity and bacterial richness was insignificant after initiation of quinolone prophylaxis (p > 0.05). Gut microbiota were significantly different between patients (p < 0.001) but non-significantly altered between the different time points before and after initiation of antibiotic prophylaxis (p > 0.05). A high relative abundance of Enterobacteriaceae > 20% during quinolone prophylaxis was found in three patients. Specific clinical scenarios (development of secondary infections during antibiotic prophylaxis or the detection of multidrug-resistant Enterobacteriaceae) characterized these patients. Sputum microbiota were not significantly altered in individuals during prophylaxis.

Conclusion

The present exploratory study with small sample size showed that inter-individual differences in diversity of gut microbiota were high at baseline, yet quinolone prophylaxis had only a moderate impact. High relative abundances of Enterobacteriaceae during follow-up might indicate failure of or non-adherence to quinolone prophylaxis. However, our results may not be clinically significant given the limitations of the study and therefore future studies are needed to further investigate this phenomenon.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fernandez J, Acevedo J, Wiest R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018;67(10):1870–80.CrossRef Fernandez J, Acevedo J, Wiest R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018;67(10):1870–80.CrossRef
2.
go back to reference Mücke MM, Rumyantseva T, Mücke VT, et al. Bacterial infection-triggered acute-on-chronic liver failure is associated with increased mortality. Liver Int. 2017;38(4):645–53.CrossRef Mücke MM, Rumyantseva T, Mücke VT, et al. Bacterial infection-triggered acute-on-chronic liver failure is associated with increased mortality. Liver Int. 2017;38(4):645–53.CrossRef
3.
go back to reference Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–37, 1437.e1–9. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–37, 1437.e1–9.
4.
go back to reference Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60(1):197–209.CrossRef Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60(1):197–209.CrossRef
5.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–60.CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–60.CrossRef
6.
go back to reference Gerbes AL, Gulberg V, Sauerbruch T, et al. German S 3-guideline “ascites, spontaneous bacterial peritonitis, hepatorenal syndrome.” Z Gastroenterol. 2011;49(6):749–79.CrossRef Gerbes AL, Gulberg V, Sauerbruch T, et al. German S 3-guideline “ascites, spontaneous bacterial peritonitis, hepatorenal syndrome.” Z Gastroenterol. 2011;49(6):749–79.CrossRef
7.
go back to reference Moreau R, Elkrief L, Bureau C, et al. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology. 2018;155(6):1816–27.CrossRef Moreau R, Elkrief L, Bureau C, et al. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology. 2018;155(6):1816–27.CrossRef
8.
go back to reference Mücke MM, Mayer A, Kessel J, et al. Quinolone- and multidrug-resistance predict failure of antibiotic prophylaxis of spontaneous bacterial peritonitis. Clin Infect Dis. 2019;70(9):1916–24.CrossRef Mücke MM, Mayer A, Kessel J, et al. Quinolone- and multidrug-resistance predict failure of antibiotic prophylaxis of spontaneous bacterial peritonitis. Clin Infect Dis. 2019;70(9):1916–24.CrossRef
9.
go back to reference Chen Y, Guo J, Qian G, et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol. 2015;30(9):1429–37.CrossRef Chen Y, Guo J, Qian G, et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol. 2015;30(9):1429–37.CrossRef
10.
go back to reference Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60(5):940–7.CrossRef Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60(5):940–7.CrossRef
11.
go back to reference Bajaj JS, Thacker LR, Fagan A, et al. Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis. JCI Insight. 2018;3(5):e98019.CrossRef Bajaj JS, Thacker LR, Fagan A, et al. Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis. JCI Insight. 2018;3(5):e98019.CrossRef
12.
go back to reference Caporaso JG, Lauber CL, Walters WA, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4516–22.CrossRef Caporaso JG, Lauber CL, Walters WA, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4516–22.CrossRef
14.
go back to reference Klindworth A, Pruesse E, Schweer T, et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res. 2013;41(1):e1.CrossRef Klindworth A, Pruesse E, Schweer T, et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res. 2013;41(1):e1.CrossRef
16.
go back to reference Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26(19):2460–1.CrossRef Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26(19):2460–1.CrossRef
17.
go back to reference Herbig A, Maixner F, Bos KI, Zink A, Krause J, Huson DH. MALT: fasat alignment and analysis of metagenomic DNA sequence data applied to the Tyrolean Iceman. bioRxiv. 2016;050559. Herbig A, Maixner F, Bos KI, Zink A, Krause J, Huson DH. MALT: fasat alignment and analysis of metagenomic DNA sequence data applied to the Tyrolean Iceman. bioRxiv. 2016;050559.
18.
go back to reference Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37(8):852–7.CrossRef Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37(8):852–7.CrossRef
19.
go back to reference Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17(1):10–2.CrossRef Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17(1):10–2.CrossRef
20.
go back to reference Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581–3.CrossRef Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581–3.CrossRef
21.
go back to reference Mandal S, Van Treuren W, White RA, Eggesbo M, Knight R, Peddada SD. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb Ecol Health Dis. 2015;26:27663. Mandal S, Van Treuren W, White RA, Eggesbo M, Knight R, Peddada SD. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb Ecol Health Dis. 2015;26:27663.
22.
go back to reference Zakrzewski M, Proietti C, Ellis JJ, et al. Calypso: a user-friendly web-server for mining and visualizing microbiome-environment interactions. Bioinformatics. 2017;33(5):782–3. Zakrzewski M, Proietti C, Ellis JJ, et al. Calypso: a user-friendly web-server for mining and visualizing microbiome-environment interactions. Bioinformatics. 2017;33(5):782–3.
23.
go back to reference Mücke MM, Mücke VM, Graf C, et al. Efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2020;11(8):e00223.CrossRef Mücke MM, Mücke VM, Graf C, et al. Efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2020;11(8):e00223.CrossRef
24.
go back to reference Fernandez J, Prado V, Trebicka J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol. 2019;70(3):398–411.CrossRef Fernandez J, Prado V, Trebicka J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol. 2019;70(3):398–411.CrossRef
25.
go back to reference Piano S, Singh V, Caraceni P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology. 2018;156(5):1368–80.CrossRef Piano S, Singh V, Caraceni P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology. 2018;156(5):1368–80.CrossRef
26.
go back to reference Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE. 2013;8(4):e60042.CrossRef Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE. 2013;8(4):e60042.CrossRef
27.
go back to reference Kaji K, Takaya H, Saikawa S, et al. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol. 2017;23(47):8355–66.CrossRef Kaji K, Takaya H, Saikawa S, et al. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol. 2017;23(47):8355–66.CrossRef
28.
go back to reference Khodamoradi Y, Kessel J, Vehreschild JJ, Vehreschild M. The role of microbiota in preventing multidrug-resistant bacterial infections. Dtsch Arztebl Int. 2019;116(40):670–6. Khodamoradi Y, Kessel J, Vehreschild JJ, Vehreschild M. The role of microbiota in preventing multidrug-resistant bacterial infections. Dtsch Arztebl Int. 2019;116(40):670–6.
29.
go back to reference Kakiyama G, Pandak WM, Gillevet PM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58(5):949–55.CrossRef Kakiyama G, Pandak WM, Gillevet PM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58(5):949–55.CrossRef
30.
go back to reference Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–8.CrossRef Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–8.CrossRef
Metadata
Title
Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis: an exploratory study
Authors
Marcus M. Mücke
Sabrina Rüschenbaum
Amelie Mayer
Victoria T. Mücke
Katharina M. Schwarzkopf
Stefan Zeuzem
Jan Kehrmann
René Scholtysik
Christian M. Lange
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2020
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-020-00389-y

Other articles of this Issue 1/2020

Gut Pathogens 1/2020 Go to the issue